BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of ...
A recent discovery by researchers from Australia and the United States has uncovered a surprising connection between a rare ...
The primary study objective of safety and tolerability was metSignificant and clinically meaningful improvements from baseline demonstrated for ...
The roots of Sandoz date back to 1886, when chemical company Kern & Sandoz was ... In 1970, Ciba and Geigy merged to form Ciba-Geigy Ltd. Ten years later, a biotechnology unit was established.
Instead, it allowed for a blood sample to be inoculated with a radioactive form of thyroid hormone ... venture between Abbott and Japan's Takeda Chemical Industries. Abbott in the 80s onwards ...
Race Oncology (ASX:RAC) has completed its Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine for ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
About CRB-701 CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using ...
IMM-1-104 aims to achieve universal-RAS activity that selectively impacts cancer cells to a greater extent than healthy cells, through Deep Cyclic Inhibition of the MAPK pathway with once-daily dosing ...
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...
JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback